Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Fleming, TR; Lin, DY
   Survival analysis in clinical trials: Past developments and future directions
   BIOMETRICS
   
   T.R. Fleming e D.Y. Lin, "Survival analysis in clinical trials: Past developments and future directions", BIOMETRICS, 56(4), 2000, pp. 971-983
2. Fleming, TR
   Design and interpretation of equivalence trials
   AMERICAN HEART JOURNAL
   
   T.R. Fleming, "Design and interpretation of equivalence trials", AM HEART J, 139(4), 2000, pp. S171-S176
3. Fleming, TR
   Surrogate end points in cardiovascular disease trials
   AMERICAN HEART JOURNAL
   
   T.R. Fleming, "Surrogate end points in cardiovascular disease trials", AM HEART J, 139(4), 2000, pp. S193-S196
4. Tabet, SR; Surawicz, C; Horton, S; Paradise, M; Coletti, AS; Gross, M; Fleming, TR; Buchbinder, S; Haggitt, RC; Levine, H; Kelly, CW; Celum, CL
   Safety and toxicity of Nonoxynol-9 gel as a rectal microbicide
   SEXUALLY TRANSMITTED DISEASES
   
   S.R. Tabet et al., "Safety and toxicity of Nonoxynol-9 gel as a rectal microbicide", SEX TRA DIS, 26(10), 1999, pp. 564-571
5. Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH
   Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
   
   B.M. Psaty et al., "Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease", J AM MED A, 282(8), 1999, pp. 786-790
6. Fleming, TR
   Issues in the design of clinical trials: Insights from the trastuzumab (Herceptin) experience
   SEMINARS IN ONCOLOGY
   
   T.R. Fleming, "Issues in the design of clinical trials: Insights from the trastuzumab (Herceptin) experience", SEMIN ONCOL, 26(4), 1999, pp. 102-107
7. Goldberg, RM; Fleming, TR
   Surgery for recurrent colon cancer - Response
   ANNALS OF INTERNAL MEDICINE
   
   R.M. Goldberg e T.R. Fleming, "Surgery for recurrent colon cancer - Response", ANN INT MED, 130(3), 1999, pp. 239-240
8. SHARPLES K; FLEMING TR; MACMAHON S; MOORE A; REID I; SCOGGINS B
   MONITORING CLINICAL-TRIALS
   New Zealand medical journal
   
   K. Sharples et al., "MONITORING CLINICAL-TRIALS", New Zealand medical journal, 111(1072), 1998, pp. 322-325
9. GOLDBERG RM; FLEMING TR; TANGEN CM; MOERTEL CG; MACDONALD JS; HALLER DG; LAURIE JA
   SURGERY FOR RECURRENT COLON-CANCER - STRATEGIES FOR IDENTIFYING RESECTABLE RECURRENCE AND SUCCESS RATES AFTER RESECTION
   Annals of internal medicine
   
   R.M. Goldberg et al., "SURGERY FOR RECURRENT COLON-CANCER - STRATEGIES FOR IDENTIFYING RESECTABLE RECURRENCE AND SUCCESS RATES AFTER RESECTION", Annals of internal medicine, 129(1), 1998, pp. 27
10. LIN DY; FLEMING TR; DEGRUTTOLA V
    ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER
    Statistics in medicine
    
    D.Y. Lin et al., "ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER", Statistics in medicine, 16(13), 1997, pp. 1515-1527
11. SHEN Y; FLEMING TR
    WEIGHTED MEAN SURVIVAL TEST STATISTICS - A CLASS OF DISTANCE TESTS FOR CENSORED SURVIVAL-DATA
    Journal of the Royal Statistical Society. Series B: Methodological
    
    Y. Shen e T.R. Fleming, "WEIGHTED MEAN SURVIVAL TEST STATISTICS - A CLASS OF DISTANCE TESTS FOR CENSORED SURVIVAL-DATA", Journal of the Royal Statistical Society. Series B: Methodological, 59(1), 1997, pp. 269-280
12. MARTINO RL; FLEMING TR; MORRELL LM; ARDALAN B; RICHMAN SP; MACDONALD JS
    PHASE-II TRIAL OF LOW-DOSE N-(PHOSPHONACETYL)-DISODIUM L-ASPARTIC ACID AND HIGH-DOSE 24-HOUR INFUSIONAL 5-FLUOROURACIL IN ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Investigational new drugs
    
    R.L. Martino et al., "PHASE-II TRIAL OF LOW-DOSE N-(PHOSPHONACETYL)-DISODIUM L-ASPARTIC ACID AND HIGH-DOSE 24-HOUR INFUSIONAL 5-FLUOROURACIL IN ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Investigational new drugs, 14(4), 1996, pp. 419-421
13. FLEMING TR; DEMETS DL
    SURROGATE END-POINTS IN CLINICAL-TRIALS - ARE WE BEING MISLED
    Annals of internal medicine
    
    T.R. Fleming e D.L. Demets, "SURROGATE END-POINTS IN CLINICAL-TRIALS - ARE WE BEING MISLED", Annals of internal medicine, 125(7), 1996, pp. 605-613
14. FLEMING TR; NEATON JD; GOLDMAN A; DEMETS DL; LAUNER C; KORVICK J; ABRAMS D; BEERS D; LOVELESS K; MARTINEZ N; MESARD CA; REVES RR; ROUFF JA; KLEIN T; MCDONALD R; SLOTTEN R; BROSGART C; DREW L; FESSEL J; HUDSON R; LOPEZ C; THOMPSON S; KUMI JO; MASTROPOLAK D; SARAVOLATZ LD; KERKERING TM; HIGGINSON RA; GERNON L; BAR M; MENDEZ D; ERNST J; SCOTT J; FINLEY B; WARD D; WISNIEWSKI T; BRANDON W; WALTER J; CALHOUN C; EBRIGHT JR; SCHUMAN P; BINCSIK A; SWANSON K; WINSLOW D; SHERIDAN A; TAYLOR V; PEREZ G; ELSADR W; GUITY C; JULEAU J; SALVATI S; DOWLING C; SALVADOR GI; BURNS AJ; LAM SH; CHILDRESS JF; DEETS DL; FLEMING TR; MEYER KH; POLLARD RB; OFALLON JR; RAHAL JJ; WALTERS L; WHITNEYWILLIAMS P; WHITLEY RJ
    INSIGHTS FROM MONITORING THE CPCRA DIDANOSINE ZALCITABINE TRIAL
    Journal of acquired immune deficiency syndromes and human retrovirology
    
    T.R. Fleming et al., "INSIGHTS FROM MONITORING THE CPCRA DIDANOSINE ZALCITABINE TRIAL", Journal of acquired immune deficiency syndromes and human retrovirology, 10, 1995, pp. 9-18
15. MACDONALD JS; FLEMING TR; PETERSON RF; BERENBERG JL; MCCLURE S; CHAPMAN RA; EYRE HJ; SOLANKI D; CRUZ AB; GAGLIANO R; ESTES NC; TANGEN CM; RIVKIN S
    ADJUVANT CHEMOTHERAPY WITH 5-FU, ADRIAMYCIN, AND MITOMYCIN-C (FAM) VERSUS SURGERY ALONE FOR PATIENTS WITH LOCALLY ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Annals of surgical oncology
    
    J.S. Macdonald et al., "ADJUVANT CHEMOTHERAPY WITH 5-FU, ADRIAMYCIN, AND MITOMYCIN-C (FAM) VERSUS SURGERY ALONE FOR PATIENTS WITH LOCALLY ADVANCED GASTRIC ADENOCARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Annals of surgical oncology, 2(6), 1995, pp. 488-494
16. BROWN TD; FLEMING TR; GOODMAN PJ; MACDONALD JS; PUGH RP; OROURKE T
    A RANDOMIZED TRIAL OF 2 SCHEDULES OF TRIMETREXATE VERSUS 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Anti-cancer drugs
    
    T.D. Brown et al., "A RANDOMIZED TRIAL OF 2 SCHEDULES OF TRIMETREXATE VERSUS 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Anti-cancer drugs, 6(2), 1995, pp. 219-223
17. LEICHMAN CG; FLEMING TR; MUGGIA FM; TANGEN CM; ARDALAN B; DOROSHOW JH; MEYERS FJ; HOLCOMBE RF; WEISS GR; MANGALIK A; MACDONALD JS
    PHASE-II STUDY OF FLUOROURACIL AND ITS MODULATION IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Journal of clinical oncology
    
    C.G. Leichman et al., "PHASE-II STUDY OF FLUOROURACIL AND ITS MODULATION IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Journal of clinical oncology, 13(6), 1995, pp. 1303-1311
18. MOERTEL CG; FLEMING TR; MACDONALD JS; HALLER DG; LAURIE JA; TANGEN CM; UNGERLEIDER JS; EMERSON WA; TORMEY DC; GLICK JH; VEEDER MH; MAILLIARD JA
    INTERGROUP STUDY OF FLUOROURACIL PLUS LEVAMISOLE AS ADJUVANT THERAPY FOR STAGE-II DUKES B2 COLON-CANCER
    Journal of clinical oncology
    
    C.G. Moertel et al., "INTERGROUP STUDY OF FLUOROURACIL PLUS LEVAMISOLE AS ADJUVANT THERAPY FOR STAGE-II DUKES B2 COLON-CANCER", Journal of clinical oncology, 13(12), 1995, pp. 2936-2943
19. FABIAN C; GIRI S; ESTES N; TANGEN CM; POPLIN E; VOGEL S; GOODWIN W; RIVKIN S; FLEMING TR; MACDONALD JS
    ADJUVANT CONTINUOUS-INFUSION 5-FU, WHOLE-ABDOMINAL RADIATION, AND TUMOR BED BOOST IN HIGH-RISK STAGE-III COLON-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP PILOT-STUDY
    International journal of radiation oncology, biology, physics
    
    C. Fabian et al., "ADJUVANT CONTINUOUS-INFUSION 5-FU, WHOLE-ABDOMINAL RADIATION, AND TUMOR BED BOOST IN HIGH-RISK STAGE-III COLON-CARCINOMA - A SOUTHWEST-ONCOLOGY-GROUP PILOT-STUDY", International journal of radiation oncology, biology, physics, 32(2), 1995, pp. 457-464
20. DEMETS DL; FLEMING TR; WHITLEY RJ; CHILDRESS JF; ELLENBERG SS; FOULKES M; MAYER KH; OFALLON J; POLLARD RB; RAHAL JJ; SANDE M; STRAUS S; WALTERS L; WHITLEYWILLIAMS P
    THE DATA AND SAFETY MONITORING BOARD AND ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME (AIDS) CLINICAL-TRIALS
    Controlled clinical trials
    
    D.L. Demets et al., "THE DATA AND SAFETY MONITORING BOARD AND ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME (AIDS) CLINICAL-TRIALS", Controlled clinical trials, 16(6), 1995, pp. 408-421
21. FLEMING TR; BROWN TD; ROSS SW; MACDONALD JS
    PHASE-II TRIAL OF TRIMETREXATE IN ADVANCED ESOPHAGEAL CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Investigational new drugs
    
    T.R. Fleming et al., "PHASE-II TRIAL OF TRIMETREXATE IN ADVANCED ESOPHAGEAL CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Investigational new drugs, 13(4), 1995, pp. 363-365
22. SCHAPER C; FLEMING TR; SELF SG; RIDA WN
    STATISTICAL ISSUES IN THE DESIGN OF HIV VACCINE TRIALS
    Annual review of public health
    
    C. Schaper et al., "STATISTICAL ISSUES IN THE DESIGN OF HIV VACCINE TRIALS", Annual review of public health, 16, 1995, pp. 1-22
23. BERENBERG JL; TANGEN C; MACDONALD JS; HUTCHINS LF; NATALE RB; OISHI N; GUY JT; FLEMING TR
    PHASE-II STUDY OF 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OFPATIENTS WITH ADVANCED GASTRIC-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Cancer
    
    J.L. Berenberg et al., "PHASE-II STUDY OF 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OFPATIENTS WITH ADVANCED GASTRIC-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Cancer, 76(5), 1995, pp. 715-719
24. ANDERSON GL; FLEMING TR
    MODEL MISSPECIFICATION IN PROPORTIONAL HAZARDS REGRESSION
    Biometrika
    
    G.L. Anderson e T.R. Fleming, "MODEL MISSPECIFICATION IN PROPORTIONAL HAZARDS REGRESSION", Biometrika, 82(3), 1995, pp. 527-541
25. GRAMBSCH PM; THERNEAU TM; FLEMING TR
    DIAGNOSTIC PLOTS TO REVEAL FUNCTIONAL FORM FOR COVARIATES IN MULTIPLICATIVE INTENSITY MODELS
    Biometrics
    
    P.M. Grambsch et al., "DIAGNOSTIC PLOTS TO REVEAL FUNCTIONAL FORM FOR COVARIATES IN MULTIPLICATIVE INTENSITY MODELS", Biometrics, 51(4), 1995, pp. 1469-1482
26. MOERTEL CG; FLEMING TR; MACDONALD JS; HALLER DG; LAURIE JA; TANGEN CM; UNGERLEIDER JS; EMERSON WA; TORMEY DC; GLICK JH; VEEDER MH; MAILLIARD JA; GRAFF J
    FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT
    Annals of internal medicine
    
    C.G. Moertel et al., "FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT", Annals of internal medicine, 122(5), 1995, pp. 321-326
27. FLEMING TR; PRENTICE RL; PEPE MS; GLIDDEN D
    SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIALAPPLICATIONS IN CANCER AND AIDS RESEARCH
    Statistics in medicine
    
    T.R. Fleming et al., "SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIALAPPLICATIONS IN CANCER AND AIDS RESEARCH", Statistics in medicine, 13(9), 1994, pp. 955-968
28. FLEMING TR
    SURROGATE MARKERS IN AIDS AND CANCER TRIALS
    Statistics in medicine
    
    T.R. Fleming, "SURROGATE MARKERS IN AIDS AND CANCER TRIALS", Statistics in medicine, 13(13-14), 1994, pp. 1423-1435
29. BUKOWSKI RM; TANGEN CM; PETERSON RF; TAYLOR SA; RINEHART JJ; EYRE HJ; RIVKIN SE; FLEMING TR; MACDONALD JS
    PHASE-II TRIAL OF DIMETHYLTRIAZENOIMIDAZOLE CARBOXAMIDE IN PATIENTS WITH METASTATIC CARCINOID - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Cancer
    
    R.M. Bukowski et al., "PHASE-II TRIAL OF DIMETHYLTRIAZENOIMIDAZOLE CARBOXAMIDE IN PATIENTS WITH METASTATIC CARCINOID - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Cancer, 73(5), 1994, pp. 1505-1508
30. LIN DY; FLEMING TR; WEI JL
    CONFIDENCE BANDS FOR SURVIVAL CURVES UNDER THE PROPORTIONAL HAZARDS MODEL
    Biometrika
    
    D.Y. Lin et al., "CONFIDENCE BANDS FOR SURVIVAL CURVES UNDER THE PROPORTIONAL HAZARDS MODEL", Biometrika, 81(1), 1994, pp. 73-81
31. MOERTEL CG; FLEMING TR; MACDONALD JS; HALLER DG; LAURIE JA
    HEPATIC TOXICITY ASSOCIATED WITH FLUOROURACIL PLUS LEVAMISOLE ADJUVANT THERAPY
    Journal of clinical oncology
    
    C.G. Moertel et al., "HEPATIC TOXICITY ASSOCIATED WITH FLUOROURACIL PLUS LEVAMISOLE ADJUVANT THERAPY", Journal of clinical oncology, 11(12), 1993, pp. 2386-2390
32. FLEMING TR; DEMETS DL
    MONITORING OF CLINICAL-TRIALS - ISSUES AND RECOMMENDATIONS
    Controlled clinical trials
    
    T.R. Fleming e D.L. Demets, "MONITORING OF CLINICAL-TRIALS - ISSUES AND RECOMMENDATIONS", Controlled clinical trials, 14(3), 1993, pp. 183-197
33. LEICHMAN CG; TANGEN C; MACDONALD JS; LEIMERT T; FLEMING TR
    PHASE-II TRIAL OF AMONAFIDE IN ADVANCED PANCREAS CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    Investigational new drugs
    
    C.G. Leichman et al., "PHASE-II TRIAL OF AMONAFIDE IN ADVANCED PANCREAS CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY", Investigational new drugs, 11(2-3), 1993, pp. 219-221
34. HARVEY WH; FLEMING TR; GOODMAN PJ; HARVEY JH; RIVKIN SE; MACDONALD JS
    PHASE-II STUDY OF TRIMETREXATE IN PREVIOUSLY UNTREATED PATIENTS WITH HEPATOCELLULAR-CARCINOMA - SOUTHWEST-ONCOLOGY-GROUP STUDY 8712
    Investigational new drugs
    
    W.H. Harvey et al., "PHASE-II STUDY OF TRIMETREXATE IN PREVIOUSLY UNTREATED PATIENTS WITH HEPATOCELLULAR-CARCINOMA - SOUTHWEST-ONCOLOGY-GROUP STUDY 8712", Investigational new drugs, 11(1), 1993, pp. 45-46
35. MOERTEL CG; FLEMING TR; MACDONALD JS; HALLER DG; LAURIE JA; TANGEN C
    AN EVALUATION OF THE CARCINOEMBRYONIC ANTIGEN (CEA) TEST FOR MONITORING PATIENTS WITH RESECTED COLON-CANCER
    JAMA, the journal of the American Medical Association
    
    C.G. Moertel et al., "AN EVALUATION OF THE CARCINOEMBRYONIC ANTIGEN (CEA) TEST FOR MONITORING PATIENTS WITH RESECTED COLON-CANCER", JAMA, the journal of the American Medical Association, 270(8), 1993, pp. 943-947
36. KOSOROK MR; FLEMING TR
    USING SURROGATE FAILURE TIME DATA TO INCREASE COST-EFFECTIVENESS IN CLINICAL-TRIALS
    Biometrika
    
    M.R. Kosorok e T.R. Fleming, "USING SURROGATE FAILURE TIME DATA TO INCREASE COST-EFFECTIVENESS IN CLINICAL-TRIALS", Biometrika, 80(4), 1993, pp. 823-833